New Strategic Alliances to Build Industry Leading Pipeline

Partnerships with Gates MRI and the Novo REPAIR Impact Fund Validate and Accelerate Development of SPR720

New Strategic Alliances to Build Industry Leading Pipeline: Partnerships with Gates MRI and the Novo REPAIR Impact Fund Validate and Accelerate Development of SPR720

By: Troy Lister, PhD, Vice President of Research and Early Development at Spero Therapeutics July 2, 2019 Since its founding, Spero has built strategic partnerships to advance its multi-asset, clinical-stage pipeline, raising approximately $44 million in committed non-dilutive funding since inception, with the potential to receive up to a total of $122 million in such funding, […]

Spero’s New Inter-agency Collaboration

By: Ankit Mahadevia Today we are pleased to announce our collaboration with BARDA, DTRA and USAMRIID for the further development of our oral carbapenem product candidate SPR994. What it means for patients A significant unmet need exists for an oral broad-spectrum antimicrobial to keep patients with complicated Gram-negative infections out of the hospital or allow them […]